Clinical Trials at Novant Health Forsyth Medical Center
As of August 2026, 24 paid clinical trials are recruiting at Novant Health Forsyth Medical Center in Winston-Salem, North Carolina. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Multiple Myeloma and Malignant Solid Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Winston-Salem
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
25 clinical trials at Novant Health Forsyth Medical Center
·Clear filters·A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Distance-Based Exercise to Preserve Function and Prevent Disability
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
Common conditions studied in Winston-Salem
- Acute Myeloid Leukemia (11 active studies)
- Multiple Myeloma (10 active studies)
- Cancer (9 active studies)
- Malignant Solid Neoplasm (7 active studies)
- Chronic Pain (6 active studies)
- Breast Cancer (5 active studies)
Leading research sponsors in Winston-Salem
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
- AbbVie
Frequently asked questions
How many paid clinical trials are currently recruiting in Winston-Salem?
There are approximately 530 recruiting clinical trials in Winston-Salem, North Carolina listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Winston-Salem pay participants?
Most recruiting trials in Winston-Salem compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Winston-Salem?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Winston-Salem?
The most common conditions under active study in Winston-Salem include Acute Myeloid Leukemia (11), Multiple Myeloma (10), Cancer (9), Malignant Solid Neoplasm (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Winston-Salem?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Winston-Salem on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Winston-Salem?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Winston-Salem?
Recruiting research sites in Winston-Salem include Wake Forest University Health Sciences, Atrium Health Wake Forest Baptist, Wake Forest University, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Winston-Salem right now?
The largest active categories in Winston-Salem are Cancer & tumors (155), Neurology & pain (35), Cardiovascular (30). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.